Medical Letter on the CDC & FDA
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC & FDA
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Botulinum Toxin
Novel method developed to quantify botulinum neurotoxin antibodies
September 5th, 2004
Scientists have applied an in vitro technique to achieve the detection and quantification of botulinum neurotoxin antibodies. According to a study from England, "Detection of Clostridium botulinum neurotoxin (BoNT) neutralizing antibodies is currently achieved using the mouse lethality assay (MLA). This technique has provided the majority of the data for vaccine development and, with the increasing use of BoNT as a therapeutic agent, the MLA is the assay of choice to evaluate 'non-responder' antisera. However, the MLA is semi-quantitative and has an animal consumption rate that raises ethical concerns. The development of an alternative is therefore desirable." ...
Source: Medical Letter on the CDC & FDA (2004-09-05)
|
